Condition

Renal Cell Cancer Metastatic

ClinicalTrials.gov condition label

Clinical trials5

Recruiting1

Common interventions5

Lead sponsors shown5

Clinical trials

5 shown

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid TumorsNCT06451497 · 2024-05-22

A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid TumorsNCT04903873 · 2021-05-31

Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.NCT04749602 · 2020-08-10

Sunitinib Treatment on Tissue Sodium Accumulation (TSS2)NCT04368546 · 2015-11-01

5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung CancerNCT01658813 · 2012-07-01

Common interventions

5-Fluorouracil and InterferonDRUG1 EU101DRUG1 NivolumabDRUG1 SunitinibDRUG1 ZM008BIOLOGICAL1

Leading sponsors

Charite University, Berlin, Germany1 Eutilex1 Kidney Cancer Research Bureau1 Western Regional Medical Center1 Zumutor Biologics Inc.1

Trial status mix

COMPLETED3

RECRUITING1

UNKNOWN1

Phase mix

PHASE23

PHASE12

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.